From tools to targets: Dementia Discovery Fund’s approach to de-risking neurology investments

In a challenging period for biotech’s specialist investors, the recent announcement that SV Health Investors’ Dementia Discovery Fund had closed a second fund stands out as a bright spot — especially given the historically perceived high risk of a dementia-focused strategy.

Heterogeneous patient populations, long development timelines, relatively poorly understood biology, lack of diagnostics and biomarkers, and few clinical success stories have long obscured the path forward for dementia drug development...